Concomitant Anti-TNF and Anti-IL-17 Therapy in Severe, Refractory Hidradenitis Suppurativa: A Case Series
Estella Bastian, Lia Bizuneh, Erin H. Amerson, Haley B. Naik
0 citationsJAAD International
Haley B. Naik
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
165Publications signalées
4074Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Hidradenitis Suppurativa and TreatmentsColorectal and Anal CarcinomasChemotherapy-related skin toxicityAcne and Rosacea Treatments and EffectsDermatological and COVID-19 studies
Publications récentes
Health System Experiences and Care Engagement in Latine Patients With Hidradenitis Suppurativa
Yanel Hernandez, Nathaly Gonzalez, Raveena Ghanshani, Herbert B. Castillo Valladares et autres
2 citationsJAMA Dermatology
Biologic therapy and risk of mental health diagnosis in patients with hidradenitis suppurativa
Afua Ofori-Darko, Devin Barzallo, Sinead M. Sinnott, Haley B. Naik et autres
2 citationsJournal of Investigative Dermatology
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension
Christopher J. Sayed, Brian Kirby, Amit Garg, Haley B. Naik et autres
8 citationsJournal of the American Academy of Dermatology
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Haley B. Naik, Steven Daveluy, Errol P. Prens, Z. Reguiaï et autres
0 citationsSKIN The Journal of Cutaneous Medicine
Lower Neighborhood Socioeconomic Status Is Associated with Moderate-Severe Hidradenitis Suppurativa: A Cross-Sectional Study
Maria Elena Sanchez-Anguiano, Krittin J. Supapannachart, Erin Amerson, Haley B. Naik et autres
0 citationsJID Innovations
63334 The impact of continuous secukinumab treatment between weeks 52–104 on draining tunnels in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE extension trial
Jennifer L. Hsiao, Vivian Y. Shi, Pierre‐André Bécherel, Z. Reguiaï et autres
0 citationsJournal of the American Academy of Dermatology
63331 Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
John R Ingram, Haley B. Naik, Christos C. Zouboulis, Gregor B. E. Jemec et autres
0 citationsJournal of the American Academy of Dermatology
64392 Patient and Dermatologists Perspectives on Hidradenitis Suppurativa Draining Tunnel Treatment and Unmet Needs
Antonio Martorell, Steven Daveluy, Paul G. Hazen, Tarannum Jaleel et autres
0 citationsJournal of the American Academy of Dermatology
63451 Efficacy of secukinumab uptitration from every 4 weeks to every 2 weeks dosing between weeks 52-104 in week 52 HiSCR non-responder patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE extension trial
Afsáneh Alavi, Aysha Badat, Falk G. Bechara, Evangelos J. Giamarellos‐Bourboulis et autres
0 citationsJournal of the American Academy of Dermatology
Prevalence of Hidradenitis Suppurativa
Dorra Bouazzi, Sabrina Mai Nielsen, Paa Gyasi Hagan, Sofia Botvid et autres
25 citationsJAMA Dermatology
0202 Neighborhood-level socioeconomic status and hidradenitis suppurativa severity
Maria Elena Sanchez-Anguiano, Krittin J. Supapannachart, Erin Amerson, Haley B. Naik et autres
0 citationsJournal of Investigative Dermatology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.